Allison Wheeler, MD
Pediatric Hematology-Oncology · Seattle, WANPI 1174736912
Payments from drug & device makers
Across 1,319 payments — averaging $995.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$652K
- Cerus Corporation$180K
- Novo Nordisk Health Care AG$112K
- Biomarin Pharmaceutical Inc.$69K
- Sanofi US Services Inc.$68K
- Novo Nordisk$30K
- plus $202K from 14 others
Across 1 payment — averaging $510.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$510
What the payments were for
- Consulting fees$206,01765%
- Speaking & faculty fees$25,4298%
- Travel & lodging$79,42625%
- Food & beverage$5,4742%
- Education$210%
- Gifts$1,3870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 1,050 | $652,330 |
| Cerus Corporation | 16 | $179,888 |
| Novo Nordisk Health Care AG | 42 | $112,323 |
| Biomarin Pharmaceutical Inc. | 14 | $69,277 |
| Sanofi US Services Inc. | 9 | $68,173 |
| Novo Nordisk | 22 | $29,878 |
| Sanofi | 21 | $28,191 |
| HEMA Biologics, LLC | 13 | $26,539 |
| Octapharma USA, Inc. | 9 | $23,843 |
| CSL Behring | 27 | $23,440 |
| Pfizer | 18 | $21,965 |
| Bayer | 27 | $20,711 |
| Genentech USA, Inc. | 21 | $20,639 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $16,375 |
| Regeneron | 3 | $14,492 |
| Bioverativ Therapeutics Inc. | 1 | $2,958 |
| Shire North American Group Inc | 11 | $1,399 |
| Spark Therapeutics, Inc. | 2 | $855 |
| Bio Products Laboratory USA, Inc. | 1 | $172 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NovoSeven$24,891
- HEMLIBRA$19,964
- ALTUVIIIO$19,805
- QFITLIA$14,423
- FIBRYGA$12,757
- HYMPAVZI$10,446
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$10,187
- Jivi$9,762
- HEMGENIX$7,455
- Alhemo$6,346
- INTERCEPT BLOOD SYSTEM FOR PLATELETS$5,555
- ADVATE$5,100
- NovoSeven RT$2,720
- SevenFact$2,500
- ADYNOVATE$1,600
- BENEFIX$1,110
- REBINYN$1,020
- NUWIQ$847
- VYNDAQEL$750
- Coagadex$172
How this compares
$1,313,467 in reported general payments places this provider in the 95th percentile of 60 pediatric hematology-oncology providers in Washington.
See all pediatric hematology-oncology providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 11 | $1,564 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Seattle
- Douglas HawkinsSeattle$7.8M
- Sarah LearySeattle$2.1M
- Adam LambleSeattle$1.3M
- James OlsonSeattle$899K
- Whitney EngSeattle$683K
- Katherine TarlockSeattle$436K
- Navin PintoSeattle$371K
- Paul CarpenterSeattle$283K
- Erin CrottySeattle$115K
- Rachel RauSeattle$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.